[Skip to Content]
[Skip to Content Landing]

You May Also Like

Article
April 1954

PHENYLBUTAZONE (BUTAZOLIDIN), A USEFUL CHEMOTHERAPEUTIC AGENT FOR HODGKIN'S DISEASE

Author Affiliations

NEW YORK

From the Hodgkin's Disease Research Laboratory and the Department of Medicine, The St. Vincent's Hospital of the City of New York.

AMA Arch Intern Med. 1954;93(4):561-570. doi:10.1001/archinte.1954.00240280081009
Abstract

IT IS THE purpose of this paper to present an evaluation of the therapeutic efficacy of phenylbutazone* in Hodgkin's disease. The study covers a period of 18 months, during which time sufficient data were accumulated on 35 patients with Hodgkin's disease to make evident a pattern of therapeutic response and to delimit its usefulness insofar as this disease is concerned.

We shall not review the literature pertaining to the chemistry or pharmacology of phenylbutazone nor its effects on diseases other than Hodgkin's disease. This has been done adequately by others,† but up to now only one reference3 has appeared in the literature as to its effect on Hodgkin's disease. This one report states briefly that after a single intramuscular injection of the drug into one patient with Hodgkin's disease there followed reduction of fever, subsidence of pain, and improvement of general condition and appetite.

MATERIAL  In Table 1 are

First Page Preview View Large
First page PDF preview
First page PDF preview
×